ClinicalTrials.Veeva

Menu

Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL

F

Federal University of São Paulo

Status and phase

Completed
Phase 4

Conditions

Cataract

Treatments

Device: AT LISA TRI
Device: AT LISA TRI TORIC

Study type

Interventional

Funder types

Other

Identifiers

NCT02770924
CAAE 49921915.1.0000.5505

Details and patient eligibility

About

The aim of this study is to evaluate the visual function of patients with bilateral implantation of the IOL trifocal ZEISS AT LISA TRI AND TRI TORIC by means of visual acuity tests with and without optical correction, sensitivity curve contrast, defocus curve and quality questionnaire visual function (VFQ-25).

Full description

Twenty patients (40 eyes) diagnosed with cataracts and cataract surgery indication will be selected to participate in this study. The surgery will be performed by the same surgeon with 2 week interval between surgery the first and second eye. After approval of the research project by the Research Ethics Committee all patients should understand and sign the Informed Consent and Informed (IC) before surgery.

All patients will be operated by conventional phacoemulsification with implantation of intraocular lens provided by the manufacturer.

Patients will have five study visits, including the preoperative visit, operative visit four postoperative visits.

All patients will be submitted to the following routine assessments preoperatively and demographic patient information will be recorded and a detailed medical history will be obtained.

  • VFQ-25 Questionnaire
  • Identification of the dominant eye;
  • Visual acuity
  • Refraction
  • Slit lamp examination
  • Tonometry
  • Self-keratometry;
  • Corneal topography;
  • Microscopy speculate
  • Fundus examination.

In addition, all routine preoperative measures will be performed. lens power calculations should be performed on both eyes to ensure qualification (lens power within the diopter range (D) available) and prepare for surgery (getting the lens). The emmetropia (± 0.5 D) should be the target of patients.

Enrollment

20 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients older than 50 years
  • Cataract diagnosis indicating surgery in both eyes
  • Corneal astigmatism to 12D (AT lisa tri toric)
  • Corneal astigmatism less than 0,75D (AT lisa tri)
  • Ability to provide consent and clarification for study participation

Exclusion criteria

  • Significant irregular corneal astigmatism as shown by Corneal topography;
  • Corneal astigmatism up 12D
  • Patients diagnosed with severe visual degenerative disorders (e.g. macular degeneration or other disorder of the retina)
  • Previous corneal surgery;
  • Amblyopia
  • Planning for multiple procedures, including IRL, LASIK, etc. during surgery or during the study
  • Endothelial dystrophy clinically significant cornea (eg, Fuchs dystrophy)
  • Corneal disease activity (eg, herpes simplex, herpes zoster, etc.)
  • Severe diabetic retinopathy
  • Retinal detachment
  • Glaucoma
  • Patients presenting illness or acute conditions or chronic severe that in the opinion of the investigator, would increase the surgical risk or confound the research results
  • Any patient who is taking part in another study involving ocular surgery

Trial design

20 participants in 2 patient groups

AT LISA TRI TORIC
Experimental group
Description:
All patients will be undergo to phacoemulsification with IOL implantation bilateral
Treatment:
Device: AT LISA TRI TORIC
AT LISA TRI
Experimental group
Description:
All patients will be undergo to phacoemulsification with IOL implantation bilateral
Treatment:
Device: AT LISA TRI

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems